SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
GEVA was delisted on the 22nd of June, 2015.
120 hedge funds and large institutions have $2.42B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2014 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 38 increasing their positions, 43 reducing their positions, and 18 closing their positions.
28% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 18
4% more funds holding
Funds holding: 115 → 120 (+5)
12% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 43
30% less call options, than puts
Call options by funds: $8.81M | Put options by funds: $12.6M
31% less capital invested
Capital invested by funds: $3.53B → $2.42B (-$1.11B)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$40.5M |
| 2 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$29.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.5M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$16M |
| 5 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCI
Columbus Circle Investors
|
-$27.4M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$18.9M |
| 3 |
PCM
Palisade Capital Management
Fort Lee,
New Jersey
|
-$12.7M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$11.9M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$5.64M |
GEVA Hedge Fund Activity: Q3 2014 in Review
120 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q3 2014, worth a combined $2.42B — down 31% from $3.53B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new GEVA positions and 18 closed out — a net gain of 5 holders — while 38 added to existing stakes and 43 trimmed.
The largest buyer was Wells Fargo, adding an estimated $40.5M. The largest seller was Columbus Circle Investors, exiting entirely with an estimated $27.4M sold.
- 120 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q3 2014, up from 115 in Q2 2014.
- Funds reported $2.42B of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q3 2014, down 31% quarter-over-quarter.
- 23 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q3 2014 and 18 closed out, a net change of +5 holders.
- The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) buyer in Q3 2014 was Wells Fargo, an estimated $40.5M added.
- The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q3 2014 was Columbus Circle Investors, an estimated $27.4M sold.
Based on aggregated 13F filings for Q3 2014.